Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A · SSE:688192
Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A — Dizal Pharmaceutical — J.P. Morgan Healthcare Conference 2026
20 slides from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A's conference presentation, Jan 15, 2026
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Xiaolin Zhang, Ph.D., Chairman and CEO January 15, 2026 1
Slide 2: Dizal: A Commercial Stage China Based Biopharmaceutical Company
Dizal: A Commercial Stage China Based Biopharmaceutical Company • A spin-off of AstraZeneca Innovative Medicine and Early Development Asia • Key disease areas include lung cancer and hematological diseases Fully integrated Two drugs One drug approved Seven candidates ~1000 capabilities: approved in
Slide 3: Highlights of Dizal's Pipeline
Highlights of Dizal’s Pipeline Program Target Most Advanced Stage Ongoing/Planned Studies Recognitions • Ph3 1L EGFR Exon20ins NSCLC • Ph3 1L EGFR PACC NSCLC • FDA and NMPA Breakthrough • Approved in US and China for • Ph3 Adjuvant EGFR Sunvozertinib EGFR r/r NSCLC with EGFR Exon20ins Exon20ins/EGFR
Slide 4: ZEGFROVY
Status: ▪ Approved in US and China for r/r NSCLC with EGFR Exon20ins mutations ▪ Ongoing pivotal studies in 1st line EGFR PACC mutaions ZEGFROVY® ▪ Ongoing pivotal adjuvant in EGFR and PACC mutated （Sunvozertinib，DZD9008） NSCLC Near Milestone: ▪ US, EU, China NDA submission, 1L EGFR Exon20ins NSCLC,
Slide 5: Zegfrovy: The Only Approved Small-Molecule Inhibitor for Patients with EGFR Exon 20 Insertion Mutations
Zegfrovy: The Only Approved Small-Molecule Inhibitor for Patients with EGFR Exon 20 Insertion Mutations WU-KONG1B: Accelerated Approval by US FDA WU-KONG6: Accelerated Approval by China NMPA 5 © Dizal Pharmaceutical. All rights reserved.
Slide 6: WU-KONG 28: Zegfrovy vs. chemo doublet in 1st line NSCLC with exon20ins
WU-KONG 28: Zegfrovy vs. chemo doublet in 1st line NSCLC with exon20ins DZD9008 300 mg Tumor assessment • Locally QD PO until PD advanced or metastatic NSCLC N = 320 Overall (cytologically or Randomization at 1:1 survival histologically) • Treatment naïve • ECOG: 0-1 Platinum-based Tumor assessment
Slide 7: Zegfrovy: 1st line NSCLC with PACC mutations
Zegfrovy: 1st line NSCLC with PACC mutations Waterfall Plot of Best Change in Tumor Size of Target Lesions ▪ Better response and deeper tumor shrinkage were observed for 300 mg group, ORR=78.6% ▪ Zegfrovy demonstrated anti-tumor efficacy in patients with different EGFR PACC/uncommon mutation either
Slide 8: Zegfrovy: 1st line NSCLC with PACC mutations Waterfall and Swimmer Plot
Zegfrovy: 1st line NSCLC with PACC mutations Waterfall and Swimmer Plot of 300 mg ORR=78.6% 8 © Dizal Pharmaceutical. All rights reserved.
Slide 9: DZD6008
Status: ▪ Positive PoC in r/r NSCLC post Tagrisso ▪ Confirmed activity DZD6008 in 1L common EGFRm ▪ Well tolerated as a single agent and in combinations Near Milestone: A BBB-penetrant 4th Generation EGFR TKI ▪ Phase 3 in 2026 © Dizal Pharmaceutical. All rights reserved. 9
Slide 10: DZD6008: A Best-in-Class 4th Generation EGFR TKI
DZD6008: A Best-in-Class 4th Generation EGFR TKI Unmet Medical Needs Ongoing Clinical Studies ▪ While chemo/bispecific antibodies in combination ▪ Monotherapy with 3rd Gen EGFR TKI showed survival benefits but — Post-3rd generation EGFR TKI failure at the cost of enhanced toxicities ▪ Combination wi
Slide 11: DZD6008: early clinical data validated concepts and showing great promises
DZD6008: early clinical data validated concepts and showing great promises Monotherapy: Clinical Proof-of-Concept in Post 3rd-Generation EGFR TKI Failed NSCLC ORR= 60% mPFS >10M China cohort (TIAN-SHAN2) Ex-China cohort (TIAN-SHAN1) Calcified Baseline Week 18 All baseline BM without prior radiation
Slide 12: DZD6008: Incidence of AEs of special interests for EGFR TKIs
DZD6008: Incidence of AEs of special interests for EGFR TKIs DZD6008 20 mg DZD6008 40 mg DZD6008 60 mg DZD6008 90 mg *Tagrisso 80 mg (N = 7) (N = 69) (N = 79) (N = 11) (N=337) n (%) n (%) n (%) n (%) n (%) All Grades Grade ≥ 3 All Grades Grade ≥ 3 All Grades Grade ≥ 3 All Grades Grade ≥ 3 All Grades
Slide 13: Golidocitinib
Status: ▪ Approved in China, r/r PTCL Near Milestone: Golidocitinib ▪ US NDA submission, r/r PTCL （DZD4205） A JAK1-only inhibitor © Dizal Pharmaceutical. All rights reserved. 13
Slide 14: Golidocitinib: First and Only JAK1 Inhibitor Approved for R/R PTCL
Golidocitinib: First and Only JAK1 Inhibitor Approved for R/R PTCL Unmet Medical Needs Go-CHOP: PTCL 1st line Study A highly heterogeneous group of non-Hodgkin's lymphomas Golidocitinib in combination with CHOP for 1st line PTCL ▪ 1L PTCL: CHOP/CHOP-like, 50-65% response, most relapse within 2 years
Slide 15: Birelentinib
Status: ▪ Phase 3 in r/r CLL/SLL ongoing Birelentinib Near Milestone: ▪ Phase 3 in 1L DLBCL, 1L （DZD8586） CLL/SLL A BBB-penetrant Lyn/BTK dual inhibitor © Dizal Pharmaceutical. All rights reserved. 15
Slide 16: Birelentinib: A Lyn/BTK Dual Inhibitor in Phase 3 Study in CLL/SLL
Birelentinib: A Lyn/BTK Dual Inhibitor in Phase 3 Study in CLL/SLL Differentiated Profile Superior Safety and Efficacy in r/r CLL/SLL – POC Study ▪ First-in-class, non-covalent, Lyn/BTK dual inhibitor ▪ Full blood-brain barrier (BBB) penetration ▪ Overcomes both BTK-dependent and BTK- independent mu
Slide 17: Birelentinib Demonstrates Superior Activities in DLBCL
Birelentinib Demonstrates Superior Activities in DLBCL Encouraging Ph2 Results in R/R DLBCL Unmet Medical Needs ▪ 1L DLBCL: R-CHOP; 30-50% refractory/relapse ▪ r/r DLBCL: poor prognosis (mOS 5-8 months) ▪ ORR of 50% ▪ No BTKi approved. Some activities in at RP2D as non-GCB DLBCL but not in GCB a sin
Slide 18: Strong Revenue Growth Driven by Zegfrovy and Golidocitinib Approvals and NRDL Listing
Strong Revenue Growth Driven by Zegfrovy and Golidocitinib Approvals and NRDL Listing US$ in million 2023 2024 2025 120 100 80 60 40 20 0 Revenue 18 Note: preliminary 2025 revenue © Dizal Pharmaceutical. All rights reserved.
Slide 19: Key Messages
Key Messages • Global NDA submissions for Zegfrovy in 1st line NSCLC with EGFR exon20ins mutations is planned in H1 2026 • DZD6008, the BBB-penetrant 4th generation EGFR TKI, showed significant clinical activities in naïve and Tagrisso treated patients • Combination of Zegfrovy and DZD6008 showed pr
Slide 20: Disclaimer
Disclaimer This document has been prepared regarding Dizal Pharmaceutical Co., Ltd., (the “Company”, together with its subsidiaries, the “Group”) solely for use at this presentation. The information contained in this document/presentation may not be used for any other purpose and must not be communi
Dizal Pharmaceutical — J.P. Morgan Healthcare Conference 2026 on 6ix